Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05169411
Other study ID # 21-018814
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date September 22, 2023
Est. completion date June 2024

Study information

Verified date November 2023
Source Children's Hospital of Philadelphia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pediatric chronic kidney disease (CKD) results from health conditions that reduce kidney function for >3 months. It can progress to end-stage kidney disease (ESKD), which requires dialysis or kidney transplant. In adults, CKD is common and caused mainly by hypertension and diabetes. CKD in childhood is rare and caused primarily by congenital anomalies of the genitourinary system and immune-mediated disorders. The best estimate of pediatric CKD prevalence is <1/15,000 pediatric population. Hypertension occurs in 50% of affected children and is a major risk factor for decline in kidney function. Several clinical practice guidelines have offered recommendations for blood pressure (BP) management in pediatric CKD; however, clinical trial and large-scale observational data are limited, leading to a weak evidence base and substantial practice variation. The purpose of PRESERVE is to provide new knowledge to inform shared decision-making regarding BP management for pediatric CKD. We will leverage the Patient-Centered Outcomes Research network (PCORnet®) infrastructure to conduct large-scale observational studies that will address BP management knowledge gaps for pediatric CKD and sub-groups for whom antihypertensive treatment and outcome associations may be different (e.g., cause of kidney disease and proteinuria). The project's specific aims are: Aim 1-Enhance the PCORnet Common Data Model (CDM) for pediatric and rare kidney disease research. We will expand and improve the PCORnet CDM with new pediatric- and kidney-specific variables, study-specific data quality optimization, and linkage with the chronic kidney disease in children (CKiD) cohort study and the US Renal Data System (USRDS). CKiD directly measures kidney function [ie, glomerular filtration rate (GFR)] and includes Ambulatory Blood Pressure Monitoring (ABPM). The USRDS provides complete capture of renal replacement therapy [(RRT) dialysis and transplant], two components of the primary clinical outcome. Aim 2-Describe and examine the effectiveness of consistent BP and urine protein monitoring for preserving kidney function. We will describe the consistency of BP and urine protein monitoring and will contrast clinic BP assessments with ABPM. In longitudinal analyses, we will evaluate the effects of consistent monitoring of BP and urine protein on kidney function decline. Aim 3-Compare the effectiveness of BP medication strategies for preserving kidney function. We will compare the effects of (1) BP levels when treatment was started, (2) choice of first-line therapies, and (3) ongoing BP control on kidney function decline. We will also assess adverse events related to hypertension management. Aim 4-Assess patients' lived experiences related to BP management. We will field a survey that examines patient-centered outcomes by level of BP control and medication management approaches. This Aim will provide information on experiences with BP management from the perspectives of patients, parents, and clinicians that will complement the clinical outcomes studied in Aims 2 and 3.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 11084
Est. completion date June 2024
Est. primary completion date February 2024
Accepts healthy volunteers No
Gender All
Age group 1 Year to 17 Years
Eligibility Inclusion Criteria: - Include: patient has an outpatient, ED, or inpatient visit with a physician - Include: 1 or more eGFR values 30-89 mL/min/1.73m2 using the CKiD U25 formula - Include: 2 or more eGFR values 30-89 mL/min/1.73m2 on different days using the CKiD U25 formula - Include: 2 eGFR values in the range 30-89 mL/min/1.73m2 using the CKiD U25 formula greater than or equal to 90 days apart. Exclusion Criteria: - Exclude: eGFR value >=90 ml/min using the CKiD U25 formula between the two qualifying eGFRs in mild-moderate range - Exclude if: Age <1 and >=18 years on CED (see below for definition of CED) - Exclude if: no nephrologist visit at any time during the study period - Exclude: if chronic dialysis on or before CED - Exclude: if kidney transplant on or before CED

Study Design


Intervention

Diagnostic Test:
Blood pressure
The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category. We will conduct additional secondary analyses for specific medications with sufficient sample sizes.
Urine protein
Evaluating urine protein for children with CKD and hypertension is another guideline recommendation, but the frequency, type of assessment (qualitative or quantitative urine protein), and utility for patients without hypertension are unclear. We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.

Locations

Country Name City State
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania

Sponsors (19)

Lead Sponsor Collaborator
Children's Hospital of Philadelphia Alfred I. duPont Hospital for Children, Ann & Robert H Lurie Children's Hospital of Chicago, Children's Hospital Medical Center, Cincinnati, Duke University, Indiana University, Johns Hopkins University, Medical College of Wisconsin, Nationwide Children's Hospital, Patient-Centered Outcomes Research Institute, Seattle Children's Hospital, Stanford University, University of Colorado, Denver, University of Florida, University of Iowa, University of Miami, University of Michigan, University of North Carolina, Chapel Hill, University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Decline in estimated glomerular filtration rate (eGFR) Time from cohort entrance (defined as day when first estimated glomerular filtration rate will be measured by the following criteria: (1) >50% decline in eGFR, as measured by the U25 formula; (2) eGFR <=15 ml/min as measured by the U25 formula); (3) initiation of chronic dialysis; or (4) kidney transplant.
U25 formula: https://doi.org/10.1016/j.kint.2020.10.047
up to 18 months
See also
  Status Clinical Trial Phase
Completed NCT05630729 - Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management N/A
Completed NCT05569746 - A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS Phase 2
Recruiting NCT03250559 - Ultrasonic vs. Fluoroscopic Guided PNL in Pediatric Renal Stones N/A
Completed NCT05064267 - Hemostatic Profiles in Pediatric CKD
Not yet recruiting NCT06430684 - Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease Early Phase 1
Recruiting NCT04752293 - Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Recruiting NCT05653492 - Safety, Feasibility, and Tolerability of Sulforaphane in Children With Chronic Kidney Disease Phase 2
Completed NCT05896345 - Shockwave Lithotripsy (SWL) Versus SWL and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone N/A
Completed NCT06087003 - Pediatric Induction Therapy in Kidney Transplantation
Not yet recruiting NCT06286098 - Alpha Lipoic Acid in Pediatrics on Hemodialysis Phase 3
Completed NCT04788394 - Renal Involvement in Hospitalized Children With COVID-19
Recruiting NCT05439980 - Improving Phosphate Control in Children With CKD
Completed NCT04010981 - Comparison of the Effectiveness of Virtual Reality and Video Assisted Exercises in Pediatric Chronic Kidney Disease. N/A
Recruiting NCT02378805 - European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Terminated NCT04132375 - Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS Phase 2/Phase 3
Completed NCT04836026 - Registry for HF20 for Pediatric CRRT Under Emergency Use Authorization
Completed NCT05388955 - Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation
Active, not recruiting NCT03719339 - VIRTUUS Children's Study
Recruiting NCT06057545 - Pharmacokinetics, Effectiveness and Tolerability of Prolonged-release Tacrolimus After Paediatric Kidney Transplantation Phase 3